Renflexis (Merck Sharp & Dohme Corp.)
Welcome to the PulseAid listing for the Renflexis drug offered from Merck Sharp & Dohme Corp.. This Tumor Necrosis Factor Blocker [EPC],Tumor Necrosis Factor Receptor Blocking Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Merck Sharp & Dohme Corp. |
| NON-PROPRIETARY NAME: | infliximab |
| SUBSTANCE NAME: | INFLIXIMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Tumor Necrosis Factor Blocker [EPC],Tumor Necrosis Factor Receptor Blocking Activity [MoA] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2017-07-01 |
| END MARKETING DATE: | 0000-00-00 |
Renflexis HUMAN PRESCRIPTION DRUG Details:
| Item Description | Renflexis from Merck Sharp & Dohme Corp. |
| LABELER NAME: | Merck Sharp & Dohme Corp. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100(mg/1) |
| START MARKETING DATE: | 2017-07-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0006-4305_80f9dcfe-a91b-405e-ae61-cc2895d43084 |
| PRODUCT NDC: | 0006-4305 |
| APPLICATION NUMBER: | BLA761054 |
Other INFLIXIMAB Pharmaceutical Manufacturers / Labelers:
